Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 2/20 | 0.72 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.72 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.72 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.72 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.72 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.72 |
| ▸ | SCN1A | P35498 | 1/20 | 0.72 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.72 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.72 |
| ▸ | HTR1A | P08908 | 2/20 | 0.62 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.62 |
| ▸ | DRD2 | P14416 | 2/20 | 0.60 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20445401 | 1.00 | ADRA2A (0.72) | ADRA2AADRA2BADRA2CADRA1DADRA1A | |
| SCHEMBL20445466 | 1.00 | ADRA2A (0.72) | ADRA2AADRA2BADRA2CADRA1DADRA1A | |
| SCHEMBL20445446 | 1.00 | ADRA2A (0.72) | ADRA2AADRA2BADRA2CADRA1DADRA1A | |
| SCHEMBL20445395 | 1.00 | ADRA2A (0.72) | ADRA2AADRA2BADRA2CADRA1DADRA1A | |
| SCHEMBL11854599 | 0.86 | ADRA2A (0.84) | ADRA2AADRA2BADRA2CADRA1DADRA1A | |
| Piperoxan SCHEMBL29404377 | 0.84 | ADRA2A (1.00) | ADRA2AADRA2BADRA2CADRA1DADRA1A | |
| Piperoxan SCHEMBL83631 | 0.84 | ADRA2A (1.00) | ADRA2AADRA2BADRA2CADRA1DADRA1A | |
| Piperoxan SCHEMBL31464193 | 0.84 | ADRA2A (1.00) | ADRA2AADRA2BADRA2CADRA1DADRA1A | |
| SCHEMBL21014258 | 0.84 | ADRA1D (0.71) | ADRA2AADRA2BADRA2CADRA1DADRA1A | |
| Piperoxan SCHEMBL12503311 | 0.83 | ADRA2A (0.97) | ADRA2AADRA2BADRA2CADRA1DADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10774074-B2 | 2-(1-heteroarylpiperazin-4-yl)methyl-1,4-benzodioxane derivatives as alpha2C antagonists | ORION CORPORATION (FI) | 2020-09-15 | — | — | US | disclosed |
| US-20190292170-A9 | 2-(1-HETEROARYLPIPERAZIN-4-YL)METHYL-1,4-BENZODIOXANE DERIVATIVES AS ALPHA2C ANTAGONISTS | ORION CORPORATION (FI) | 2019-09-26 | — | — | US | disclosed |
| US-20180215739-A1 | 2-(1-HETEROARYLPIPERAZIN-4-YL)METHYL-1,4-BENZODIOXANE DERIVATIVES AS ALPHA2C ANTAGONISTS | ORION CORPORATION (FI) | 2018-08-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180215739-A1 | 2-(1-HETEROARYLPIPERAZIN-4-YL)METHYL-1,4-BENZODIOXANE DERIVATIVES AS ALPHA2C ANTAGONISTS | OPRM1, HTR2C, ADRA2C | ADRA2A 13/4885ADRA2B 39/4885ADRA2C 3/4885 |
| US-10774074-B2 | 2-(1-heteroarylpiperazin-4-yl)methyl-1,4-benzodioxane derivatives as alpha2C antagonists | OPRM1, HTR2C, ADRA2C | ADRA2A 13/4885ADRA2B 39/4885ADRA2C 3/4885 |
| US-20190292170-A9 | 2-(1-HETEROARYLPIPERAZIN-4-YL)METHYL-1,4-BENZODIOXANE DERIVATIVES AS ALPHA2C ANTAGONISTS | OPRM1, HTR2C, ADRA2C | ADRA2A 13/4885ADRA2B 39/4885ADRA2C 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.